AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 160 filers reported holding AERIE PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $105,000 | +40.0% | 6,923 | -31.1% | 0.00% | – |
Q2 2022 | $75,000 | -13.8% | 10,049 | +5.0% | 0.00% | – |
Q1 2022 | $87,000 | -17.9% | 9,575 | -37.2% | 0.00% | – |
Q4 2021 | $106,000 | +211.8% | 15,255 | +413.8% | 0.00% | – |
Q3 2021 | $34,000 | +70.0% | 2,969 | +134.5% | 0.00% | – |
Q2 2021 | $20,000 | -67.2% | 1,266 | -63.4% | 0.00% | – |
Q1 2021 | $61,000 | +84.8% | 3,461 | +45.2% | 0.00% | – |
Q4 2020 | $33,000 | +22.2% | 2,384 | +2.4% | 0.00% | – |
Q3 2020 | $27,000 | -25.0% | 2,327 | -5.5% | 0.00% | – |
Q2 2020 | $36,000 | -16.3% | 2,462 | -22.1% | 0.00% | – |
Q1 2020 | $43,000 | -78.3% | 3,160 | -61.5% | 0.00% | – |
Q4 2019 | $198,000 | +40.4% | 8,200 | +11.7% | 0.00% | – |
Q3 2019 | $141,000 | -89.9% | 7,339 | -84.5% | 0.00% | – |
Q2 2019 | $1,398,000 | +68.8% | 47,327 | +171.6% | 0.00% | – |
Q1 2019 | $828,000 | +24.9% | 17,426 | -5.1% | 0.00% | – |
Q4 2018 | $663,000 | -46.1% | 18,363 | -8.2% | 0.00% | -100.0% |
Q3 2018 | $1,231,000 | -34.7% | 19,999 | -28.4% | 0.00% | 0.0% |
Q2 2018 | $1,886,000 | +5.7% | 27,927 | -15.1% | 0.00% | 0.0% |
Q1 2018 | $1,784,000 | -1.7% | 32,875 | +8.3% | 0.00% | 0.0% |
Q4 2017 | $1,815,000 | -6.2% | 30,364 | -23.7% | 0.00% | 0.0% |
Q3 2017 | $1,935,000 | -52.5% | 39,819 | -48.6% | 0.00% | -50.0% |
Q2 2017 | $4,071,000 | +0.8% | 77,462 | -13.0% | 0.00% | 0.0% |
Q1 2017 | $4,040,000 | +12.1% | 89,083 | -6.5% | 0.00% | 0.0% |
Q4 2016 | $3,605,000 | +3.3% | 95,259 | +3.0% | 0.00% | 0.0% |
Q3 2016 | $3,489,000 | +99.4% | 92,442 | -7.0% | 0.00% | +100.0% |
Q2 2016 | $1,750,000 | +40.3% | 99,451 | -3.0% | 0.00% | 0.0% |
Q1 2016 | $1,247,000 | -46.7% | 102,553 | +6.8% | 0.00% | -50.0% |
Q4 2015 | $2,339,000 | +47.9% | 96,067 | +7.8% | 0.00% | +100.0% |
Q3 2015 | $1,581,000 | -2.4% | 89,112 | -2.9% | 0.00% | 0.0% |
Q2 2015 | $1,620,000 | -49.9% | 91,796 | -11.0% | 0.00% | -50.0% |
Q1 2015 | $3,231,000 | +45.1% | 103,095 | +35.1% | 0.00% | +100.0% |
Q4 2014 | $2,227,000 | +71.8% | 76,308 | +21.8% | 0.00% | 0.0% |
Q3 2014 | $1,296,000 | +747.1% | 62,656 | +914.7% | 0.00% | – |
Q2 2014 | $153,000 | -83.1% | 6,175 | -85.5% | 0.00% | -100.0% |
Q1 2014 | $905,000 | +18000.0% | 42,727 | +15437.1% | 0.00% | – |
Q4 2013 | $5,000 | – | 275 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |